Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 251

Results For "CRO"

4402 News Found

ProBioGen’s growth strategy continues successfully
News | March 03, 2023

ProBioGen’s growth strategy continues successfully

Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team


Department of Pharmaceuticals to celebrate 5th Jan Aushadhi Diwas on March 7
News | March 01, 2023

Department of Pharmaceuticals to celebrate 5th Jan Aushadhi Diwas on March 7

Jan Aushadhi Diwas celebrations to generate awareness about the usages of generic medicines and benefits of Jan Aushadhi Pariyojana


LifeSigns launches smart ward with wireless patient monitoring technology
News | March 01, 2023

LifeSigns launches smart ward with wireless patient monitoring technology

Amala Hospital partners with LifeSigns to provide revolutionary technology for the first time in the State


India hospital network launched to initiate life-saving colon cancer trial
News | February 28, 2023

India hospital network launched to initiate life-saving colon cancer trial

Twelve hospitals across India will be part of the network which will support the trial in India


Granules India gets USFDA approval for Losartan Potassium Tablets USP, 25 mg, 50 mg, and 100 mg
Drug Approval | February 27, 2023

Granules India gets USFDA approval for Losartan Potassium Tablets USP, 25 mg, 50 mg, and 100 mg

Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure.


Sanofi India posts Q4 CY22 PAT at Rs. 130.9 Cr
News | February 24, 2023

Sanofi India posts Q4 CY22 PAT at Rs. 130.9 Cr

The company has reported total income of Rs. 691.9 crores during the quarter ended December 31, 2022


No link between the use of ranitidine and cancer risk, claims Nature
News | February 24, 2023

No link between the use of ranitidine and cancer risk, claims Nature

N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.


MEI Pharma and Infinity Pharmaceuticals inks merger agreement to advance three promising clinical oncology candidates
Clinical Trials | February 24, 2023

MEI Pharma and Infinity Pharmaceuticals inks merger agreement to advance three promising clinical oncology candidates

Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months